Unharmonious ivonescimab reveal for Summit
The same trial that sent Summit up 272% sees the stock crash 36%.
Genor goes one better
Can activity at CTLA-4 be added to PD-1 x VEGF blockade?
Ivo combo beats Tevimbra, but can it beat Keytruda?
The PD-1 x VEGF molecule's latest win comes from Akeso's Harmoni-6 trial.
BridgeBio enters the pan-KRAS game
Meanwhile, Akeso challenges Moderna and BioNTech with an mRNA neoantigen play.
ELCC 2025 – BioNTech impresses in small-cell lung
In first-line SCLC BNT327 looks better than Tecentriq, but data will need to be replicated outside China.
Summit looks to repeat ivo's Chinese success
Akeso scored in the Harmoni-A trial, and now Summit must do the same in Harmoni.
Akeso keeps cadonilimab in China
The anti-PD-1 x CTLA-4 bispecific impresses in cervical cancer, but US plans are on ice.
